NeuroBo Pharmaceuticals Stock (NASDAQ:NRBO)
Previous Close
$4.56
52W Range
$2.89 - $6.75
50D Avg
$3.96
200D Avg
$3.99
Market Cap
$22.86M
Avg Vol (3M)
$109.14K
Beta
-0.41
Div Yield
-
NRBO Company Profile
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
NRBO Performance
Peer Comparison
Ticker | Company |
---|---|
CDIO | Cardio Diagnostics Holdings, Inc. |
ZURA | Zura Bio Limited |
ATNF | 180 Life Sciences Corp. |
BDRX | Biodexa Pharmaceuticals Plc |
VRAX | Virax Biolabs Group Limited |
QNRX | Quoin Pharmaceuticals, Ltd. |
KPRX | Kiora Pharmaceuticals, Inc. |
BWV | Onconetix, Inc. |
PXMD | PaxMedica, Inc. Common Stock |
REVB | Revelation Biosciences, Inc. |
PHIO | Phio Pharmaceuticals Corp. |
HILS | Tharimmune, Inc. |
ALLR | Allarity Therapeutics, Inc. |
SONN | Sonnet BioTherapeutics Holdings, Inc. |